Exosomes in Inflammatory Bowel Disease: What Have We Learned So Far?

Author(s): Haichao Wang, Chen Ye, Yaling Wu, Pengyu Yang, Chunqiu Chen, Zhanju Liu, Xiaolei Wang*

Journal Name: Current Drug Targets

Volume 21 , Issue 14 , 2020

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Inflammatory bowel disease (IBD) is an immune-mediated chronic inflammatory disease. Although the etiology is uncertain, there is marked disbalance of mucosal immune responses in part shaped by genetic susceptibility and intestinal microbial dysbiosis. Suppressing inflammatory activity adequately and maintaining this suppression are the main goals of current therapies. However, corticosteroids are only suitable for therapy of active disease, and the effects of immunosuppressive agents are mainly limited to maintenance of remission. Biologics have become widely available and provide therapeutic benefits to IBD patients. However, only a part of patients benefits from them. Thus, there is an urgent need for the development of new substances in the therapy of IBD. Exosomes are nanosized lipid vesicles identified recently. They are secreted from all living cells and then distributed in various human body fluids. The components, such as microRNAs and functional proteins, secreted by exosomes in different cells have been reported to be involved in the pathogenesis of IBD. Therefore, exosomes have the potential to become appealing particles in treating IBD as a cell-free therapeutic approach as well as biomarkers for diagnosis and monitoring disease status. Further studies are needed to investigate the practicality, safety and desirable effects of exosomes in clinical applications in IBD.

Keywords: Exosomes, inflammatory bowel disease, pathogenesis, cell-free therapy, clinical application, microRNAs.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 21 October, 2020
Page: [1448 - 1455]
Pages: 8
DOI: 10.2174/1389450121666200428102330
Price: $65

Article Metrics

PDF: 30